Next-Generation Immune Checkpoint Inhibitors in Gastrointestinal Cancers: Mechanisms, Resistance, and Emerging Therapeutic Strategies
TL;DR
This review explains how cancer cells bypass standard therapies and highlights next-generation immune targets currently being developed to overcome resistance, and examines how combining new immune-boosting drugs with traditional treatments like chemotherapy, radiation, and novel targeted therapies can weaken cancer defenses.
Abstract
Simple Summary Gastrointestinal cancers remain among the most challenging diseases to treat because many tumors contain complex immune system suppression mechanisms that stop the body from destroying cancer cells. While current immunotherapy drugs have transformed care for a small group of patients, most gastrointestinal tumors quickly resist these treatments. This review explains how cancer cells bypass standard therapies and highlights next-generation immune targets currently being developed to overcome this resistance. We examine how combining new immune-boosting drugs with traditional treatments like chemotherapy, radiation, and novel targeted therapies can weaken cancer defenses. Finally, we explore advanced blood tests and digital tissue profiling methods designed to help doctors predict which patients will benefit most from these therapies. By connecting basic tumor biology with innovative clinical strategies, this review aims to help researchers design smarter, more focused and effective treatment combinations for patients with gastrointestinal cancers.